Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia

American Heart Journal

Volumn 145, Issue 6, 2003, Pages 999-1005

  Mozas, P ^a   Castillo, S ^a   Reyes, G ^a   Tejedor, D ^a   Civeira, F ^b   Garcia Alvarez I ^b   Puzo, J ^c   Cenarro, A ^b   Alonso, R ^d   Mata, P ^d   Pocovi M ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c HOSPITAL SAN JORGE   (Spain)

^d Unidad de Lipidos   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; AUTOSOMAL DOMINANT DISORDER; BODY MASS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; ANALYSIS OF VARIANCE; GENETICS; HETEROZYGOTE; MIDDLE AGED;

ADULT; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED;

EID: 0038620489     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(02)94788-5     Document Type: Article

References (45)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 1995. p. 1981-2030.
2. Heath KE, Gahan M, Whittall RA, et al. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolemia: update, new features and mutation analysis. Atherosclerosis 2001;154:243-6.
3. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis 1999;142:105-15.
4. Sijbrands EJ, Westendorp RG, Lombardi PM, et al. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis 2000;149:421-5.
5. Sijbrands EJ, Westendorp RG, Defesche JC, et al. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 2001;322:1019-23.
6. Heiberg A, Slack J. Family similarities in the age at coronary death in familial hypercholesterolemia. BMJ 1977;2:493-5.
7. Ferriéres J, Lambert J, Lussier-Cacan S, et al. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995;92:290-5.
8. Wiklund O, Angelin B, Olofsson SO, et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990;335:1360-3.
9. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990;322:1494-9.
10. Vuorio AF, Turtola H, Piilahti KM, et al. Familial hypercholesterolemia in the Finnish north Karelia: a molecular, clinical, and genealogical study. Arterioscler Thromb Vasc Biol 1997;17:3127-38.
11. Curtiss LK, Boisvert WA. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 2000;11:243-51.
12. Hixson JE. Apolipoprotein E polymorphism affect atherosclerosis in young males. Arterioscler Thromb 1991;11:1237-44.
13. Wilson PW, Schaefer EJ, Larson MG, et al. Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol 1996;16:1250-5.
14. Eto M, Watanabe K, Chonan N, et al. Familial hypercholesterolemia and apolipoprotein E4. Atherosclerosis 1988;72:123-8.
15. De Knijff P, Stalenhoef AF, Mol MJ, et al. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1990; 83:89-97.
16. Kitahara M, Shinomiya M, Shirai K, et al. Frequency and role of apo E phenotype in familial hypercholesterolemia and non-familial hyperlipidemia in the Japanese. Atherosclerosis 1990;82:197-204.
17. Hill JS, Hayden MR, Frohlich J, et al. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991;11:290-7.
18. Gylling H, Aalto-Setala K, Kontula K, et al. Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia. Arterioscler Thromb 1991; 11:1368-75.
19. Kotze MJ, De Villiers WJ, Steyn K, et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb 1993;13:1460-8.
20. Ferriéres J, Sing CF, Roy M, et al. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: sex-specific effects. Arterioscler Thromb 1994;14:1553-60.
21. Lindahl G, Mailly F, Humphries S, et al. Apolipoprotein E pheno-type and lipoprotein(a) in familial hypercholesterolaemia: implication for lipoprotein(a) metabolism. Clin Invest Med 1994;72: 631-8.
22. Tonstad S, Leren TP, Sivertsen M, et al. Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway. Arterioscler Thromb Vasc Biol 1995;15:1009-14.
23. Betard C, Kessling AM, Roy M, et al. Influence of genetic variability in the nondeletion LDL-receptor allele on phenotypic variation in French-Canadian familial hypercholesterolemia heterozygotes shoring a "null" LDL-receptor gene defect. Atherosclerosis 1996; 119:43-55.
24. Carmena-Ramon R, Real JT, Ascaso JF, et al. Effect of apolipoprotein E genotype on lipid levels and response to diet in familial hypercholesterolemia. Nutr Metab Cardiovasc Dis 2000;10:7-13.
25. Bertolini S, Cantafora A, Averna M, et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol 2000;20:E41-52.
26. Lambert M, Assouline L, Feoli-Fonseca JC, et al. Determinants of lipid level variability in French-Canadian children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2001;21: 979-84.
27. WHO Human Genetics Program. Familial Hypercholesterolaemia, a global perspective. Ginebra: WHO; 1999.
28. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000; 46:1956-67.
29. Miller S, Dykes D, Polensky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
30. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990;31:545-8.
31. Pocovi M, Cenarro A, Civeira F, et al. Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136→Ser) variant in multigenerational pedigree studies. Atherosclerosis 1996;122:33-46.
32. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
33. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al, Seven Countries Study Research Group. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med 2000;342:1-8.
34. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 papulations from 21 countries in four continents. Circulation 1994;90:583-612.
35. Scuteri A, Bos AJ, Zonderman AB, et al. Is the apoE4 allele an independent predictor of coronary events? Am J Med 2001;110: 28-32.
36. Wilson PW, Myers RH, Larson MG, et al, The Framingham Offspring Study. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. JAMA 1994;272:1666-71.
37. Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001;154:529-37.
38. Ilveskoski E, Perola M, Lehtimaki T, et al. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 1999;100:608-13.
39. Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian Simvastatin Survival Study. Circulation 2000;101: 1366-71.
40. de Knijff P, Havekes LM. Apolipoprotein E as a risk factor for coronary heart disease: a genetic and molecular biology approach. Curr Opin Lipidol 1996;7:59-63.
41. Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a "thrifty" allele? Ann Hum Genet 1999; 63(Pt 4):301-10.
42. Frikke-Schmidt R, Nordestgaard BG, Agerholm-Larsen B, et al. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res 2000;41:1812-22.
43. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
44. Curtiss LK, Boisvert WA. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 2000;11:243-51.
45. Humphries SE, Talmud PJ, Hawe E, et al. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 2001;358:115-9.